Advertisement

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial

      Abstract

      Background: Nasal challenge studies have suggested histamine and cysteinyl leukotrienes are important proinflammatory mediators in allergic rhinitis. This study was designed to determine the efficacy of montelukast, a cysteinyl leukotriene receptor antagonist, administered alone or concomitantly with loratadine, an H1-receptor antagonist, in seasonal allergic rhinitis. Objective: The purpose of this study was to determine the effect of concomitant use of montelukast and loratadine in the treatment of seasonal allergic rhinitis. Methods: In this multicenter (N = 12) double-blind, randomized, parallel-group, placebo-controlled 2-week trial, 460 men and women, aged 15 to 75 years, with spring seasonal allergic rhinitis were randomly allocated to receive 1 of the following 5 treatments: montelukast 10 or 20 mg, loratadine 10 mg, montelukast 10 mg with loratadine 10 mg, or placebo, once daily in the evening. The primary end point was daytime nasal symptoms score (average of congestion, rhinorrhea, itching, and sneezing). Other end points were eye symptoms, nighttime symptoms, individual daytime nasal symptoms, global evaluations (patient’s and physician’s), and rhinoconjunctivitis quality-of-life scores. Results: Concomitant montelukast with loratadine improved the primary end point significantly (P < .001) compared with placebo and each agent alone. Compared with placebo, montelukast with loratadine also significantly improved eye symptoms, nighttime symptoms, individual daytime nasal symptoms, global evaluations, and quality of life. Montelukast alone and loratadine alone caused modest improvements in rhinitis end points. All treatments were similarly well tolerated. Conclusions: Concomitant montelukast with loratadine provided effective treatment for seasonal allergic rhinitis and associated eye symptoms with a safety profile comparable with placebo. (J Allergy Clin Immunol 2000;105:917-22.)

      Keywords

      Abbreviations:

      ANOVA: (Analysis of variance), CI: (Confidence intervals), LS: (Least square), RQLQ: (Rhinoconjunctivitis Quality-of-Life Questionnaire)
      To read this article in full you will need to make a payment

      References

        • Nathan RA
        • Meltzer EO
        • Selner JC
        • Storms W
        Prevalence of allergic rhinitis in the United States.
        J Allergy Clin Immunol. 1997; 99: S808-S814
        • Meltzer EO
        • Nathan RA
        • Selner JC
        • Storms W
        Quality of life and rhinitic symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaires.
        J Allergy Clin Immunol. 1997; 99: S815-S819
        • Juniper EF
        Measuring health-related quality of life in rhinitis.
        J Allergy Clin Immunol. 1997; 99: S742-S749
        • Fireman P
        Treatment strategies designed to minimize medical complications of allergic rhinitis.
        Am J Rhinol. 1997; 11: 95-102
        • Suonpaa J
        Treatment of allergic rhinitis.
        Ann Med. 1996; 28: 17-22
        • Bousquet J
        • Vignola AM
        • Campbell AM
        • Michel FB
        Pathophysiology of allergic rhinitis.
        Int Arch Allergy Immunol. 1996; 110: 207-218
        • Lewis RA
        • Austen F
        • Soberman RJ
        Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases.
        N Engl J Med. 1990; 323: 645-655
        • Knapp HR
        • Murray JJ
        Leukotrienes as mediators of nasal inflammation.
        Adv Prostaglandin Thromboxane Leukot Res. 1994; 22: 279-288
        • Marom Z
        • Shelhamer JH
        • Bach MK
        • Morton DR
        • Kaliner M
        Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro.
        Am Rev Respir Dis. 1982; 126: 449-451
        • Okuda M
        • Watase T
        • Mezawa A
        • Liu CM
        The role of leukotriene D4 in allergic rhinitis.
        Ann Allergy. 1988; 60: 537-540
        • Lewis RA
        • Austen F
        • Soberman RJ
        Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases.
        N Engl J Med. 1990; 323: 645-655
        • Naclerio RM
        • Baroody FM
        • Togias AG
        The role of leukotrienes in allergic rhinitis: a review.
        Am Rev Respir Dis. 1991; 143: S91-S95
        • Hay DWP
        • Torphy TJ
        • Undem BJ
        Cysteinyl leukotrienes in asthma: old mediators up to new tricks.
        TIPS. 1995; 16: 304-309
        • Busse WW
        The role of leukotrienes in asthma and allergic rhinitis.
        Clin Exp Allergy. 1996; 26: 868-879
        • Jones TR
        • Labelle M
        • Belley M
        • Champion E
        • Charette L
        • Evans J
        • et al.
        Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist.
        Can J Physiol Pharm. 1994; 73: 191-201
        • Reiss TF
        • Chervinsky P
        • Dockhorn RJ
        • Shingo S
        • Seidenberg BC
        • Edwards TB
        Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma; a multicenter, randomized, double-blind trial.
        Arch Intern Med. 1998; 150: 1213-1220
        • Jeal W
        • Faulds D
        Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis.
        Drugs. 1997; 53: 257-280
        • Simons FE
        Histamine and H1-receptor antagonists in allergic disease.
        Marcel Dekker Inc, New York1996
        • Donnelly AL
        • Glass M
        • Minkwitz MC
        • Casale TB
        The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis.
        Am J Respir Crit Care Med. 1995; 151: 1734-1739
        • Knapp HR
        Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor.
        N Engl J Med. 1990; 323: 1745-1748
        • Reicin A
        • White R
        • Weinstein S
        • Finn A
        • Nguyen H
        • Peszek I
        • et al.
        Montelukast, a leukotriene-receptor antagonist, in combination with loratadine, an H1-receptor antagonist, in the treatment of chronic asthma; a multicenter, randomized double-blind study.
        Am J Respir Crit Care Med. 1998; 157: A416
        • Roquet A
        • Dahlén B
        • Kumlin M
        • Ihre E
        • Anstrén G
        • Binks S
        • et al.
        Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics.
        Am J Respir Crit Care. 1997; 155: 1856-1863
        • Dockhorn RJ
        • Bergner A
        • Connell JT
        • Falliers CJ
        • Grabiec SV
        • Weiler JM
        • et al.
        Safety and efficacy of loratadine (Sch-29851): a new nonsedating antihistamine in seasonal allergic rhinitis.
        Ann Allergy. 1987; 58: 407-411